沙美特罗替卡松对慢性阻塞性肺疾病稳定期患者肺功能的影响研究

Research on the Effects of Salmeterol Xinafoate and Fluticasone Propionate on the Lung Function in COPD Patients in Stable Phase

目的:探讨沙美特罗替卡松治疗慢性阻塞性肺疾病(COPD)稳定期患者的临床疗效,以及对肺功能等影响。方法:收集符合标准的患者100例,采用随机数字的方法分为观察组和对照组各50例,均给予基础治疗,对照组加用丙酸氟替卡松气雾剂,观察组加用沙美特罗替卡松粉吸入剂,疗程均为12周,比较二者临床效果。结果:12周疗程结束后,观察组患者临床总有效率92.00%,高于对照组的76.00%(P<0.05)。两组患者治疗前肺功能(FVC、FEV1和FEV1/FVC)、痰液IL-8、6MWT和MBS等比较,差异无统计学意义(P>0.05);两组患者各项指标较治疗前均改善(P<0.05),但是观察组患者改善更明显(P<0.05)。观察组患者急性加重发生率16.00%,低于对照组的34.00%,差异有统计学意义(P<0.05)。结论:沙美特罗替卡松可有效改善COPD稳定期患者的肺功能,从而减轻胸闷、气促等临床症状,提高生活质量,降低急性发作频率,安全性高,值得临床推广应用。

Objective： To investigate the clinical therapeutic effects of salmeterol xinafoate and fluticasone propionate on patients with chronic obstructive pulmonary disease （ COPD ） in stable phase, and the effects on the lung function and so on. Method： 100 patients meeting the criteria were collected and randomly divided into observation group and control group, 50 patients in each group; all the patients were given with basic therapies, additionally, the control group was supplemented with fluticasone propionate aerosol, while the observation group supplemented with salmeterol xinafoate and fluticasone propionate powder for inhalation, and the courses of treatment of both groups were 12 weeks ; The clinical therapeutic effects of the two groups were compared. Result： After 12-week course of treatment, the clinical total effective rate of the observation group was 92.00%, higher than that of the control group （ 76.00% ） （ P〈0.05 ）. The differ- enees in pre-therapy lung function （ FVC, FEV1 and FEV1/FVC ）, sputum [L-8 level, 6MWT and MBS and so on between the patients of the two groups were statistically insignificant （ P〉O. 05 ） ; each index of both groups was improved when compared with that before the therapies （ P〈0.05 ） , but that of the observation group was improved more significantly （ P〈0.05 ）. The incidence of acute exacerbation of the patients of the observation group was 16.00%, lower than that of the control group （ 34.00% ） and the difference was statistically significant （ P〈0.05 ）. Conclusion： Salmeterol xinafoate and fluticasone propionate can effectively improve the lung function in COPD patients in stable phase, consequently lighten the clinical symptoms such as chest distress and short breath, elevate life quality, decrease acute episode frequency, is high safe, and worthy of clinical application. Key words： Salmeterol; Fluticasone propionate; Chronic obstructive pulmonary disease; Stable phase ; Lung function